VCL 6365

Drug Profile

VCL 6365

Alternative Names: CMV prophylactic DNA vaccine - Vical; CyMVectin; Cytomegalovirus DNA vaccine monovalent - Vical; Cytomegalovirus prophylactic vaccine - Vical; gB CMV vaccine - Vical; Vaxfectin; Vaxfectin formulated cytomegalovirus prophylactic DNA vaccine - Vical

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vical
  • Class Cytomegalovirus vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cytomegalovirus infections

Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cytomegalovirus infections(Prevention) in USA (IM, Injection)
  • 18 May 2016 Vical and the Virginia Commonwealth University withdraw a phase I study for Cytomegalovirus infections (Prevention) in USA prior to enrolment (NCT02594566)
  • 16 Oct 2015 Vical and the Virginia Commonwealth University plan a phase I study for Cytomegalovirus infections (Prevention) in USA (NCT02594566)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top